Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

40 results about "Bone erosion" patented technology

Bone erosion is the loss of bone from disease processes. Erosive arthritis is joint inflammation (arthritis) with bone destruction, and such conditions include rheumatoid arthritis. Bone erosion is the loss of bone in a certain area, rather than a change in bone density, which is found in osteoporosis. Surprisingly, bone erosion is not found in osteoarthritis.

Devices and methods for modulation of bone erosion

ActiveUS20130253413A1Preventing bone erosionImprovement of individual ankle score parameterSpinal electrodesArtificial respirationRANKLPhysical therapy
Devices and methods for stimulation of the vagus nerve to modulate (e.g., reduce, suppress, etc.) bone erosion. Methods and apparatus for modulating bone erosion may modulate levels of Receptor Activator for Nuclear Factor κB Ligand (RANKL), and / or to modulate (increase, enhance, etc.) osteoprotegerin (OPG) and / or OPG / RANKL ratio. Devices may include electrical stimulation devices that may be implanted, and may be activated to apply current for a proscribed duration, followed by a period without stimulation.
Owner:SETPOINT MEDICAL CORP

Method, code, and system for assaying joint deformity

A method, machine-readable storage medium embodying computer-readable code and automated system for assaying or monitoring the extent of joint or bone deformity reported by a summarized score that may include joint space narrowing, bone erosion and periarticular osteoporosis in a joint-degenerative or joint-damaging disease in a subject are disclosed. From a digitized image of one of the subject's straight bone terminated with a joint such as fingers, coordinates of right and left bone contours of a selected middle or proximal phalange are determined, and these coordinates are in turn used to determine the coordinates of a minimum width in the middle region of the phalange and one or more apices in a region adjacent at least one side of a joint of the selected phalange. These latter coordinates are used in selecting a reference joint contour representing normal-bone contour for that phalange, or the contour of the patient phalange from an earlier x-ray image. Guided by the reference joint contour, a region of the selected joint of the patient is analyzed to assay or monitor the extent of joint or bone deformity in the subject.
Owner:COMPUMED

Anti human RANKL monoclonal antibodies developed by PAE technology and uses thereof

The invention discloses antibodies that bind high specificity to human RANKL (Receptor Activator for Nuclear Factor kappa B Ligand), wherein, the antibodies are used for the treatment of bone erosion caused by astogeny, hormonotherapy, postmenopausal osteoporosis, bone metastasis, and inflammation. The invention also discloses DNA sequences and supposed amino acid sequences of the antibodies.
Owner:刘庆法

Pharmaceutical composition for treating femoral head necrosis and preparation method thereof

The invention provides a pharmaceutical composition for treating femoral head necrosis and a preparation method thereof. The pharmaceutical composition disclosed by the invention comprises the following components in parts by weight: 1-5 parts of pseudo-ginseng, 5-20 parts of herba epimedii, 1-10 parts of carthamus tinctorius, 5-30 parts of the root of red-rooted salvia, 5-20 parts of drynaria rhizome, 5-20 parts of teasel root, 1-15 parts of corydalis tuber, and 1-15 parts of the root of bidentate achyranthes. The traditional Chinese medicine granules disclosed by the invention have the characteristics of definite curative effect, stable quality and the like, is convenient to carry and take, have the functions of invigorating the circulation of blood, dispersing blood stasis, tonifying kidneys and reinforcing bones, and are used for treating gore blockage, deficiency of kidneys and bone erosion; symptoms include pain of hip bone, especially at night, inhibited bending and stretching, and soreness and weakness of waist and knees; and the above symptoms appear in the early stage and the middle stage of femoral head necrosis.
Owner:BEIJING ZHENDONG GUANGMING PHARMA RES INST

Chinese medicine preparation for treating femoral head necrosis

The invention discloses a Chinese medicine preparation for treating femoral head necrosis. According to ancient Chinese medicine books, femoral head necrosis belongs to diseases of bone erosion, heumatism and the like, and the diseases can be resulted from congenitally deficiency, acquired malnutrition, work and leisure, trauma, maltreatment and therapeutic errors. The Chinese medicine preparation is prepared by boiling Chinese medicines, namely, pyrola, holly leaves, autumn zephyrlily herb, root of crinite uraria, banian leaves, stylophorum lasiocarpum, root of schoch craspedolobium, cow marrow, deer sinew, tiger bone glue, mutton marrow and glaucousback with the functions of tonifying the liver and kidney, strengthening tendons and bones, promoting blood circulation to remove blood stasis and activating main and collateral channels, in water to be prepared into decoction. Clinical tests show that the total effective rate is 89.4%, which is remarkably superior to that of a control group.
Owner:尹爱斌

Application of CK2 inhibitor in preparation of rheumatoid arthritis treatment drugs

InactiveCN112274642ADisease mitigation scoreNo toxicityOrganic active ingredientsAntipyreticDiseaseSide effect
The invention provides application of a CK2 inhibitor in the preparation of rheumatoid arthritis treatment drugs. The CK2 inhibitor can significantly slow down disease scores of collagen-induced arthritis (CIA) mice, reduce synovitis and bone erosion degree, has no obvious organ toxicity and side effects, and is suitable for the preparation of rheumatoid arthritis treatment drugs.
Owner:PEOPLES HOSPITAL PEKING UNIV

Application of ginkgolic acid in preparation of medicine for preventing and/or treating diseases caused by overactivity of osteoclast

The invention belongs to the field of medicines, relates to novel pharmaceutical application of ginkgolic acid and particularly relates to application of ginkgolic acid (C17:1), which is a syzygiumtetragonum extract having a structural formula show in the specification, in preparation of a medicine for preventing and / or treating diseases caused by overactivity of osteoclast. The ginkgolic acid (C17:1) is capable of preventing nuclear translocation of NFATc1 and inhibiting differentiation and bone erosion of osteoclast and thus is used for preparing the medicine for preventing and treating the diseases including osteoporosis, osteolysis, rheumatoid arthritis, multiple myeloma, Paget's disease, hypercalcemia of tumors, osteogenesis imperfect, alveolar bone deficiency or bone loss caused during immunosuppressive therapy or long-term use of glucocorticoid.
Owner:FUDAN UNIV

Pharmaceutical application of caffeic acid 3, 4-dihydroxyl phenethylester

Belonging to the technical field of medicine application, the invention discloses pharmaceutical application of caffeic acid 3, 4-dihydroxyl phenethylester. A prevention and / or treatment medicine prepared from the caffeic acid 3, 4-dihydroxyl phenethylester (CADPE) can be used for inhibiting osteoclast differentiation, inhibiting an osteoclast bone erosion function, promoting osteoblast differentiation, and promoting an osteoblast bone formation function. The medicine can be used for preventing and / or treating osteoclast activity abnormality caused diseases, which include osteoporosis, rheumatoid arthritis, periodontitis, tooth loss, Paget's disease, rickets, osteoclastoma, myeloma bone disease and cancer bone metastasis caused bone destruction, etc.
Owner:EAST CHINA NORMAL UNIV

Targeted controlled-release anti-arthritis medicinal preparation and preparation method thereof

The invention belongs to the technical field of polymer chemistry, biomedical materials and pharmacy, and discloses a targeted controlled-release anti-arthritis medicinal preparation and a preparationmethod thereof. The pharmaceutical preparation is a drug-loaded micelle, the drug-loaded micelle is composed of a segmented copolymer PEG-PPS and tripterine, and the tripterine is loaded in the micelle formed by the segmented copolymer PEG-PPS. The preparation method comprises the following preparation steps: (1) dissolving 20-80 parts by mass of PEG-PPS and 1-10 parts by mass of tripterine in 5-10 parts by volume of tetrahydrofuran; and (2) under ultrasonic dispersion, adding the solution obtained in the step (1) into 50-100 parts by volume of water, carrying out vacuum distillation to remove tetrahydrofuran, and carrying out repeated ultrafiltration and sterile microporous filtration membrane filtration to obtain the anti-arthritis nano-drug preparation. The medicinal preparation disclosed by the invention is sensitive to rheumatoid arthritis inflammation, controllable release of the medicine can be realized, and joint synovitis and bone erosion can be obviously inhibited.
Owner:PEOPLES HOSPITAL OF HENAN PROV

Pharmaceutical Composition for Preventing or Treating Osteoporosis Which Comprises Neuropeptide Y as Active Ingredient

The present invention relates to a pharmaceutical composition for preventing or treating osteoporosis which comprises neuropeptide Y as an active ingredient. The neuropeptide Y according to the present invention reduces the expression of a cell adhesion factor in osteoblasts in which a Y1 receptor is present, and consequently an effect of releasing a haematopoietic stem cell from bone marrow into the blood is excellent. When a haematopoietic stem cell is released into the blood, the number of osteoclasts which induce an osteoporotic lesion by differentiation from the haematopoietic stem cell decreases, and thus progression of a bone erosion caused by osteoclasts can be prevented. Accordingly, the neuropeptide Y which is an active ingredient of the composition of the present invention is useful as a therapeutic agent for osteoporosis.
Owner:KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND

Method, code, and system for assaying joint deformity

A method, machine-readable storage medium embodying computer-readable code and automated system for assaying or monitoring the extent of joint or bone deformity reported by a summarized score that may include joint space narrowing, bone erosion and periarticular osteoporosis in a joint-degenerative or joint-damaging disease in a subject are disclosed. From a digitized image of one of the subject's straight bone terminated with a joint such as fingers, coordinates of right and left bone contours of a selected middle or proximal phalange are determined, and these coordinates are in turn used to determine the coordinates of a minimum width in the middle region of the phalange and one or more apices in a region adjacent at least one side of a joint of the selected phalange. These latter coordinates are used in selecting a reference joint contour representing normal-bone contour for that phalange, or the contour of the patient phalange from an earlier x-ray image. Guided by the reference joint contour, a region of the selected joint of the patient is analyzed to assay or monitor the extent of joint or bone deformity in the subject.
Owner:BI XIAOLI +1

Artificial peptidomimetic as well as preparation method and application thereof

The invention provides an artificial peptidomimetic. The structural formula of the artificial peptidomimetic is as shown in formula 1. The invention also provides a preparation method and application of the artificial peptidomimetic. The preparation method provided by the invention is reasonable in raw material selection, easy to obtain, simple in preparation process and easy to industrialize. The artificial peptidomimetic provided by the invention can be used for preparing medicines for preventing or treating redness and swelling of joints or / and swelling of joints or / and bone erosion of joints or / and joint deformation or / and reduction of joint bone density, and can also be used for preparing medicines for preventing or treating and inhibiting inflammation-related cytokines IL-1beta or / and IL-8 or / and TNF-alpha.
Owner:WUHAN UNIV

Application of B cell vaccine in preparation of drugs for treating rheumatoid arthritis

The present invention discloses an application of a B cell vaccine in preparation of drugs for treating rheumatoid arthritis and the B cell vaccine having the application. Compared with drug treatment, the B cell vaccine has the following advantages of being smaller in dosage, lower in administration frequency, longer in maintenance period, and simple and convenient in subcutaneous injection, cantreat diseases through autoimmune regulation functions, can effectively control the diseases, reduces bone erosion and joint destruction, and is free of immune tolerance problems in autotransfusion and small in side effects.
Owner:PEOPLES HOSPITAL PEKING UNIV

Combination therapy of an SODm and a corticosteroid for prevention and/or treatment of inflammatory bone or joint disease

InactiveUS20060035876A1Effective treatmentReduce doseBiocideOrganic active ingredientsSuperoxide dismutase mimeticsOsteoblast
The present invention relates to pharmaceutical compositions and methods of using such compositions for the treatment of inflammatory diseases of the bone and joints. The compositions comprise a catalyst for the dismutation of superoxide, which is a non-proteinaceous mimetic of superoxide dismutase, in combination with a corticosteroid. The combination is substantially more effective than either the superoxide dismutase mimetic or the corticosteroid given alone at the same dose. Treatment with the combination beneficially alters the progression of the inflammatory bone and joint disease as measured histologically in diminished bone resorption and infiltration of inflammatory cells; as measured radiographically in diminished joint erosion, and diminished bone erosion and osteophyte formation; and as measured histomorphometrically in decreased bone resorption measurements of eroded surface and / or osteoclast surface relative to bone surface, and increased bone formation measurements of osteoblast surface relative to bone surface.
Owner:METAPHORE PHARMA

Plaster for treating hyperosteogeny and bone erosion rheumatism

The invention particularly discloses a plaster for treating hyperosteogeny and bone erosion rheumatism, belonging to the technical field of traditional Chinese medicines. The plaster for treating hyperosteogeny and bone erosion rheumatism is prepared from eupolyphaga, rhizoma ligustici wallichii, cortex eucommiae, papaya, semen strychni, zaocys dhumnade, scorpion, safflower, radix clematidis, radix saposhnikoviae, frankincense and myrrh according to a certain proportion. The invention has reasonable compatibility, convenient use, significant curative effect, low cost and no side effect and can effectively relieve the pain of patients.
Owner:刘成玉

Medicine and preparation for treating joint diseases

The invention discloses a medicine and a preparation for treating joint diseases, belonging to the field of traditional Chinese medicine. Among the medicinal materials used according to the invention, deglued antler, ass-hide glue, Chinese cinnamon and scalded rhizome drynariae are used as monarch drug with effects of tonifying the kidney and strengthening tendons and bones; radix notoginseng, scorpion, spatholobus stem, ass-hide glue, vinegar processed turtle shell and radix gentianae macrophyllae are used as ministerial drug with effects of supporting healthy energy and eliminating pathogenic factors; rhizome coptidis, cortex lycii radicis, sweet wormwood, bupleurum falcatum, rhizome anemarrhenae, Astragalus root, blighted wheat and calcined oyster are used as conductant drug with effects of clearing away heat, removing moisture and invigorating qi; the medicinal materials are combined to take effects of supporting healthy energy, eliminating pathogenic factors, promoting bone growth, and expelling toxin. The medicine disclosed by the invention can be prepared into an oral preparation such as pills, powder, granules and ointment according to routine pharmaceutical adjuvants and process. According to clinic trails, the medicine disclosed by the invention has good therapeutic effect on joint pain or bone erosion and destruction caused by rheumatoid arthritis, osteoarthritis, spondylitis ankylopoietica, osteoarticular tuberculosis and so on, as well as reactive arthritis.
Owner:王钢

Water soluble haloanilide calcium-release calcium channel inhibitory compounds and methods to control bone erosion and inflammation associated with arthritides

A compound that is selected from the group consisting of 3-(3,4-dichloroanilino)-3-oxopropanoic acid (hereinafter “DCOPA”); N-methyl-DCOPA; N,2-dimethyl-DCOPA; 2-methyl-DCOPA; isobutyl-DCOPA; N-methyl-isobutyl DCOPA; 3-(3,4-bibromoanilino)-3-oxopropanoic acid; and analogs of DCOPA; and analogs of 3-(3,4-bibromoanilino)-3-oxopropanoic acid; and pharmaceutically acceptable salts of these compounds, are disclosed. A method of controlling bone erosion in a patient comprising administering to the patient a therapeutically effective amount of at least one of these compounds, or a pharmaceutically acceptable salt of at least one of these compounds, is provided. A method of reducing inflammation in a patient having an inflammatory condition comprising administering to the patient a therapeutically effective amount of at least one of these compounds, or a pharmaceutically acceptable salt of at least one of these compounds is provided.
Owner:WEST VIRGINIA UNIVERSITY

Wind-dispelling stagnation-eliminating traditional Chinese medicine composition and application thereof

ActiveCN110123868ARelieve joint swellingRelieve inflammation in the bodyAntipyreticAnalgesicsDiseaseRANKL Protein
The invention discloses a wind-dispelling stagnation-eliminating traditional Chinese medicine composition which is formed by compatibility of whole scorpion, centipede, radix astragali and black beancoat. The invention also discloses an application of the composition in preparation of drugs for treating rheumatoid arthritis bone erosion and rheumatoid arthritis. The wind-dispelling stagnation-eliminating traditional Chinese medicine composition is found out to inhibit the expression of IL-6 and RANKL in various cells of CIA mice joint parts, increase the expression of osteoprotegerin OPG, reduce the number of osteoclasts, increase bone density, alleviate bone erosion in CIA mice, and effectively alleviate CIA mice joint bone swelling and reduce injury of synovium of joint, and has pharmaceutical application prospect for related diseases.
Owner:JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE

Plaster for treating hyperosteogeny and bone erosion rheumatism

The invention particularly discloses a plaster for treating hyperosteogeny and bone erosion rheumatism, belonging to the technical field of traditional Chinese medicines. The plaster for treating hyperosteogeny and bone erosion rheumatism is prepared from eupolyphaga, rhizoma ligustici wallichii, cortex eucommiae, papaya, semen strychni, zaocys dhumnade, scorpion, safflower, radix clematidis, radix saposhnikoviae, frankincense and myrrh according to a certain proportion. The invention has reasonable compatibility, convenient use, significant curative effect, low cost and no side effect and caneffectively relieve the pain of patients.
Owner:刘成玉

Application of proteus mirabilis outer membrane vesicle in preparation of medicine for preventing or treating osteolytic diseases

The invention discloses application of proteus mirabilis outer membrane vesicle in preparation of a medicine for preventing or treating osteolytic diseases. The proteus mirabilis outer membrane vesicle inhibits miR96-5p expression and promotes Abca1 expression, thereby inhibiting an MAPK / ERK pathway and causing osteoclast differentiation to be blocked; the proteus mirabilis outer membrane vesicle induces release of MPT-related cytochrome c to cause a mitochondrial structure to be damaged, increase production of active oxygen and cause increase of osteoclast apoptosis. The proteus mirabilis outer membrane vesicle not only significantly inhibits differentiation and functions of RANKL-induced osteoclasts in vitro, but also can improve bone metabolism imbalance caused by OVX and bone erosion caused by CII in vivo, and provides a new idea for preventing or treating the osteolytic diseases.
Owner:SOUTHERN MEDICAL UNIVERSITY

Application of ginkgolic acid in the preparation of drugs for preventing and/or treating diseases caused by overactivation of osteoclasts

The invention belongs to the field of medicaments and relates to a new medicinal application of ginkgolic acid. In particular, it relates to the application of ginkgolic acid (C17:1) extracted from rose apple with the following structural formula in the preparation of medicines for preventing and / or treating diseases caused by overactivation of osteoclasts. The ginkgolic acid (C17:1) inhibits osteoclast differentiation and bone erosion by preventing NFATc1 nuclear translocation, and is used for the prevention and treatment of osteoporosis, osteolysis, rheumatoid arthritis, multiple myeloma, Paget's Diseases, hypercalcemia of malignant tumors, osteogenesis imperfecta, alveolar bone loss, or bone loss caused by immunosuppressive treatment or long-term use of glucocorticoids.
Owner:FUDAN UNIV

Application of combination of lactobacillus plantarum NA136 and cannabidiol monomer in preparation of product for treating rheumatoid arthritis

The invention discloses application of a combination of lactobacillus plantarum NA136 and a cannabidiol monomer in preparation of a product for treating rheumatoid arthritis, and belongs to the field of functional food microorganisms. The concentration of the lactobacillus plantarum NA136 is 2*10 <9>-2*10 <10> CFU; the concentration of cannabidiol monomer is 2.4 mg / mL; and the lactobacillus plantarum NA136 and the cannabidiol monomer are used separately. Tests prove that the joint application of the lactobacillus plantarum NA136 strain and the cannabidiol monomer can relieve the arthritis symptom of rats; bone erosion and cartilage degeneration are reduced; the product can reduce inflammatory reaction, reduce the levels of inflammatory factors IL-17 and TNF-alpha, and improve the level of an anti-inflammatory factor IL-10; and the content of lipopolysaccharide in serum is reduced. During the onset of rheumatoid arthritis, the immunoglobulin IgG level is reduced. The composition has the effect of preventing and / or treating rheumatoid arthritis.
Owner:JILIN ACAD OF AGRI SCI

Traditional Chinese medicine preparation for treating femoral head necrosis

ActiveCN103263537AUps and downs are closely relatedSkeletal disorderUnknown materialsGLYCYRRHIZA EXTRACTKidney
The invention discloses a traditional Chinese medicine preparation for treating femoral head necrosis. According to traditional Chinese medicine, femoral head necrosis belongs to bone numbness and bone erosion. Essence is stored in kidneys; essence generates marrow filled in bones, therefore, the relationship between development, growth and vicissitude of kidneys and vicissitude of kidney essence is close; if the kidney essence and marrow sea are deficient, evil obstruction of main and collateral channels is influenced; the pathogenesis of femoral head necrosis is sputum blood resistance. The traditional Chinese medicine preparation disclosed by the invention is prepared by decocting ampelopsis aconitifolia bge, ceylon cynoglossum, cantonese speranskia, clematis armandii, Japanese ardisia herb, tricuspid cudrania bark, fried eucommia ulmoides, teasel root, tortoise plastron, panax japonicas and roasted liquorice into decoction with water; clinical tests prove that the total effective rate is up to 97.7%; and the traditional Chinese medicine preparation disclosed by the invention is worthy of popularizing and applying in clinic.
Owner:启东市第五人民医院

External plaster for treating bone erosion, osteomyelitis, bone impediment and rheumatism and preparation method thereof

The invention discloses an external plaster for treating bone erosion, osteomyelitis, bone impediment and rheumatism and a preparation method thereof. The external plaster is prepared from the following raw materials of angelica sinensis, dragon's blood, olibanum (prepared), myrrh (prepared), flos carthami, catechu, rehmannia, rhizoma bletillae, asarum, astragalus membranaceus, codonopsis pilosula, rhizoma drynariae, teasel root, salvia miltiorrhiza, eupolyphaga, rehmannia glutinosa, notopterygium root, divaricate saposhnikovia root, radix angelicae pubescentis, scorpion, radix gentianae macrophyllae, divaricate saposhnikovia root, eucommia ulmoides, cassia twig, pangolin, cinnamon, ligusticum wallichii, agkistrodon halys, lycopodium clavatum, scorpion, pseudo-ginseng, parasitic loranthus, rhizoma corydalis, radix aconiti lateralis praeparata slice, radix clematidis, sesame oil and red lead 2; and the raw materials are crushed, decocted, added with oil to collect paste, and spread on cotton cloth after hot melting. Through local and acupoint application, the external plaster has the effects of promoting blood circulation to remove blood stasis, dredging channels and collaterals, reducing swelling and resolving mass, regulating qi to alleviate pain, dispelling wind and eliminating dampness, and dispelling cold and activating collaterals, has a good treatment effect on femoral head necrosis, osteomyelitis, ankylosing spondylitis, bone ununion, rheumatism, rheumatoid, lumbar disc herniation, cervical spondylosis, gonitis and hyperostosis, and has no toxic or side effect.
Owner:闫三毛

Water Soluble Haloanilide Calcium-Release Calcium Channel Inhibitory Compounds and Methods to Control Bone Erosion and Inflammation Associated with Arthritides

A compound that is selected from the group consisting of 3-(3,4-dichloroanilino)-3-oxopropanoic acid (hereinafter “DCOPA”); N-methyl-DCOPA; N,2-dimethyl-DCOPA; 2-methyl-DCOPA; isobutyl-DCOPA; N-methyl-isobutyl DCOPA; 3-(3,4-bibromoanilino)-3-oxopropanoic acid; and analogs of DCOPA; and analogs of 3-(3,4-bibromoanilino)-3-oxopropanoic acid; and pharmaceutically acceptable salts of these compounds, are disclosed. A method of controlling bone erosion in a patient comprising administering to the patient a therapeutically effective amount of at least one of these compounds, or a pharmaceutically acceptable salt of at least one of these compounds, is provided. A method of reducing inflammation in a patient having an inflammatory condition comprising administering to the patient a therapeutically effective amount of at least one of these compounds, or a pharmaceutically acceptable salt of at least one of these compounds is provided.
Owner:WEST VIRGINIA UNIVERSITY

Pyrazole-containing betulinic acid derivative as well as preparation method and application thereof

The invention relates to betulinic acid derivatives containing pyrazole and a preparation method and application of the betulinic acid derivatives, in particular to compounds with the structure shown in the general formula I. Definitions of all groups are shown in the specification. A rat arthritis model is induced through sodium iodoacetate, and the change of the degree of arthralgia is observed; an in-vitro induced differentiation system is adopted, and the osteoclast differentiation and inflammatory factor generation level of the osteoclast precursor is observed. Results show that the compound adopted by the invention has inhibitory activity on osteoclast differentiation and inflammatory factor generation, has a good treatment effect on osteoarthritis and joint inflammation diseases with bone destruction, bone erosion and synovitis as pathological characteristics, and has an ideal clinical application prospect.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products